2025
Towards a dynamic model to estimate evolving risk of major bleeding after percutaneous coronary intervention
Hurley N, Desai N, Dhruva S, Khera R, Schulz W, Huang C, Curtis J, Masoudi F, Rumsfeld J, Negahban S, Krumholz H, Mortazavi B. Towards a dynamic model to estimate evolving risk of major bleeding after percutaneous coronary intervention. PLOS Digital Health 2025, 4: e0000906. PMID: 40560847, PMCID: PMC12193038, DOI: 10.1371/journal.pdig.0000906.Peer-Reviewed Original ResearchNational Cardiovascular Data RegistryPercutaneous coronary interventionPrescription of medicationsRisk predictionArea under the receiver operating characteristic curveRisk prediction modelTreatment decision makingIndividualized carePatient dischargeData registryRisk estimatesRisk modelPrimary outcomeIndex admissionRisk informationModerate riskCoronary interventionPercutaneous coronary intervention proceduresRisk factorsPatient characteristicsIn-hospital bleeding eventsHigh riskLow riskMedical historyRegistry
2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply